Related Experiment Video

Updated: May 27, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.2K

PIM kinase inhibition counters resistance to radiotherapy and chemotherapy in human prostate cancer

Anne Rajkumar-Calkins1, Vinay Sagar2, Jian Wang3

  • 1Department of Radiation Oncology, Vanderbilt University Medical Center, 2220 Pierce Ave, B1003 PRB, Nashville, TN 37232, USA; Department of Radiation Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|February 20, 2025
PubMed
Abstract

Insights

PIM kinase inhibition overcomes resistance to docetaxel and radiotherapy in prostate cancer models. This strategy shows promise for treating resistant prostate cancers when combined with standard therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • PIM kinases are implicated in prostate cancer progression and treatment resistance.
  • These kinases play roles in DNA damage repair, metabolism, proliferation, and survival.

Purpose of the Study:

  • To investigate if PIM kinase inhibition can overcome treatment resistance to radiotherapy and docetaxel in prostate cancer.
  • To evaluate PIM inhibition in preclinical models of prostate cancer.

Main Methods:

  • PIM inhibition effects on DNA damage repair and cell survival were assessed in prostate cancer cell lines.
  • Tumor growth was monitored in mice with xenografts treated with PIM inhibitors, radiotherapy, or docetaxel.
  • RNA-Seq and immunostaining were used to analyze molecular changes.

Main Results:

  • PIM inhibition reduced DNA repair, proliferation, and survival in prostate cancer cells.
  • PIM inhibition enhanced the efficacy of radiotherapy and docetaxel in reducing tumor size in both hormone-dependent and -independent xenografts.
  • Gene expression analysis revealed altered ribosomal and cardiomyocyte signaling pathways, with changes in COX-2 and MDM2 protein levels.

Conclusions:

  • PIM kinase inhibition effectively addresses treatment resistance to docetaxel and radiotherapy in preclinical prostate cancer models.
  • PIM inhibitors represent a potential therapeutic strategy when combined with standard treatments for resistant prostate cancer.
  • Clinical trials are warranted to test PIM inhibitors in patients with treatment-resistant prostate cancer.
Keywords:
DocetaxelModel organisms/animal models of cancerPIM kinaseProstate cancerRadiationRadiosensitization

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K